BLU News and Press, BELLUS Health Inc. From 03/25/20

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...

- BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due - - 4.77 million BELLUS Health common shares to be issued in consideration - BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS He...

BELLUS Health ( BLU ) has completed patient enrollment for the RELIEF trial , its dose-escalation Phase 2 study of BLU-5937 in patients with refractory chronic cough. More news on: BELLUS Health, Healthcare stocks news, Read more ...

- On track to report topline data from the RELIEF trial in mid-2020 - BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and...

BELLUS Health ( BLU ): FY GAAP EPS of -C$0.73. More news on: BELLUS Health, Earnings news and commentary, Healthcare stocks news, , Read more ...

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial a...

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto B...